Investor Presentaiton
Income Statement - Q3 & 9M'FY20
Particulars¹
Q3'FY19
Q3'FY20
YoY Growth
9M'FY19
9M'FY20
YoY Growth
FY'19
Total Revenue from Operations
2,377
2,315
(3%)
6725
6,763
1%
9,111
Pharmaceuticals
1,424
1,450
2%
3943
4,231
7%
5,349
Life Science Ingredients
899
797
(11%)
2633
2,356
(11%)
3,545
Drug Discovery & Development Solutions
54
68
26%
149
176
18%
217
Total Expenditure
1,884
1,819
(3%)
5344
5,364
0%
7,372
Other Income
29
6
42
28
36
Segment EBITDA
519
528
2%
1450
1,478
2%
1,835
Pharmaceuticals
388
411
6%
1087
1,127
4%
1,372
Life Science Ingredients
126
100
(21%)
344
313
(9%)
445
Drug Discovery & Development Solutions
5
17
270%
19
39
108%
18
Corporate (Expenses)/Income
4
(15)
(27)
(40)
(60)
Reported EBITDA
522
513
(2%)
1423
1,438
1%
1,775
Depreciation and Amortization
98
113
15%
276
333
21%
371
Finance Cost
53
72
36%
158
216
37%
220
Profit before Tax
371
328
(12%)
989
889
(10%)
1,184
Exceptional Items
(15)
(35)
(45)
(35)
(280)
Profit before Tax (After Exceptional Items)
356
293
(18%)
944
855
(9%)
904
Tax Expenses (Net)
88
90
2%
266
217
(19%)
327
Minority Interest
7
0
4
0
3
PAT
261
203
(22%)
674
638
(5%)
574
Earnings Per Share - Face Value Re. 1 (Rs.)
16.7
12.8
43.2
40.0
36.9
Segment EBITDA Margins
21.8%
22.8%
21.6%
21.9%
20.1%
Pharmaceuticals
27.2%
28.4%
27.6%
26.6%
25.7%
Life Science Ingredients
14.0%
12.6%
13.1%
13.3%
12.6%
Drug Discovery & Development Solutions
8.6%
25.4%
12.5%
22.0%
8.3%
Reported EBITDA Margin
22.0%
22.2%
21.2%
21.3%
19.5%
Net Margin
11.0%
8.8%
10.0%
9.4%
6.3%
In Q3'FY20 and 9M'FY20 Exceptional charge of Rs 23.3 Crore was related to prepayment of high yield bonds and NCDs and Rs 11.3
Crore related to asset write-off. Q3'FY19 and 9M'FY19 charge of 15 Crore and Rs 45 Crore, respectively, was due to IFC Stock
settlement charge
1.
All figures are in Rs Crore unless otherwise stated
2.
Pharmaceuticals segment includes India Branded Pharmaceuticals business
JUBILANT
LIFESCIENCESView entire presentation